Loading...
•
Dec 31, 2019
Heron Therapeutics Q4 2019 Earnings Report
Heron Therapeutics reported financial results and highlighted recent corporate updates.
Key Takeaways
Heron Therapeutics reported CINV franchise net product sales were $35.1 million, up 22% from the same period in 2018. Net loss for the quarter was $57.9 million, or $0.65 per share.
Heron resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-011 in September 2019.
The FDA has extended the review period for the NDA for HTX-011 by up to three months, with a new PDUFA goal date of June 26, 2020.
Heron's New Drug Submission (NDS) for HTX-011 was granted Priority Review status and accepted by Health Canada in December 2019.
CINV franchise net product sales were $35.1 million, up 22% from the same period in 2018.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.com Forward Guidance
Heron expects 2020 net product sales for the CINV franchise of $70 million to $80 million and the CINV franchise to return to growth in 2021 and beyond.